LQ091

LQ091 is a preclinical-stage, orally administered VHH nanobody (single-domain antibody) being developed by Novamab for the treatment of autoimmune diseases. As a VHH nanobody, it is derived from the variable domain of heavy-chain-only antibodies found in camelids, offering high stability and the potential for oral delivery, which is unconventional for most antibody-based therapies. While the specific biological target remains undisclosed by the developer, the drug is designed to modulate immune responses associated with autoimmune conditions. It represents part of Novamab's effort to transition biologic therapies from injectable to oral formats using their proprietary nanobody platform.